Wim A. van der Steeg

Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment

John J.P. Kastelein, Wim A. van der Steeg, Ingar Holme et al. · Circulation · 2008 · 468 citations

High-Density Lipoprotein Cholesterol, High-Density Lipoprotein Particle Size, and Apolipoprotein A-I: Significance for Cardiovascular Risk

Wim A. van der Steeg, Ingar Holme, S. Matthijs Boekholdt et al. · Journal of the American College of Cardiology · 2008 · 377 citations

Metabolic Syndrome, High-density Lipoprotein Cholesterol, Cardiovascular Epidemiology +10

Value of Low-Density Lipoprotein Particle Number and Size as Predictors of Coronary Artery Disease in Apparently Healthy Men and Women

Karim El Harchaoui, Wim A. van der Steeg, Erik S.G. Stroes et al. · Journal of the American College of Cardiology · 2007 · 239 citations

Metabolic Syndrome, Cardiovascular Epidemiology, Cardiovascular Disease +11

Role of the Apolipoprotein B–Apolipoprotein A-I Ratio in Cardiovascular Risk Assessment: A Case–Control Analysis in EPIC-Norfolk

Wim A. van der Steeg, S. Matthijs Boekholdt, Evan A. Stein et al. · Annals of Internal Medicine · 2007 · 164 citations

Quantification of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in dried blood spots by liquid chromatography–triple quadrupole mass spectrometry

Rob ter Heine, Hilde Rosing, E.C.M. van Gorp et al. · Journal of Chromatography B · 2008 · 114 citations

Protease Inhibitors, Proteomic Technology, Biochemistry +13